Blum Veronika, Müller Beat, Hofer Silvia, Pardo Esther, Zeidler Kristin, Diebold Joachim, Strobel Klaus, Brand Christoph, Aebi Stefan, Gautschi Oliver
Division of Medical Oncology.
Institute of Pathology.
Eur J Dermatol. 2018 Feb 1;28(1):78-81. doi: 10.1684/ejd.2017.3209.
Programmed cell death ligand 1 (PD-L1) is frequently expressed in cutaneous squamous cell cancer (CSCC) and preliminary data from an ongoing clinical trial suggest that programmed death receptor 1 (PD-1) checkpoint inhibitors may be useful to treat patients with metastatic non-melanoma skin cancer. To report a series of three patients with advanced CSCC treated with nivolumab, showing that commercially available PD-1 checkpoint inhibitors may be useful in non-melanoma skin cancer patients without access to a clinical trial. All patients had previous chemotherapy. All cancers were PD-1 ligand (PD-L1)-positive based on immunohistochemistry. Patients consented to off-label therapy with nivolumab, which is commercially available in Switzerland. Two patients had a partial tumour response, and have been receiving therapy for more than 12 months. One patient had stable disease after three months, and therapy is also ongoing. So far, no severe adverse effects have occurred. Our cases confirm previous reports demonstrating a clinical effect and tolerability of PD-1 checkpoint inhibitors for heavily pre-treated patients with metastatic CSCC. Commercially available PD-1 checkpoint inhibitors may be useful in these patients who should be considered for PD-1 checkpoint inhibitor therapy, preferentially within clinical trials.
程序性细胞死亡配体1（PD-L1）在皮肤鳞状细胞癌（CSCC）中经常表达，一项正在进行的临床试验的初步数据表明，程序性死亡受体1（PD-1）检查点抑制剂可能对治疗转移性非黑色素瘤皮肤癌患者有用。报告3例接受纳武单抗治疗的晚期CSCC患者，表明市售的PD-1检查点抑制剂可能对无法参加临床试验的非黑色素瘤皮肤癌患者有用。所有患者均曾接受过化疗。根据免疫组织化学，所有癌症均为PD-1配体（PD-L1）阳性。患者同意接受纳武单抗的非标签治疗，该药在瑞士有市售。2例患者出现部分肿瘤缓解，且接受治疗已超过12个月。1例患者在3个月后病情稳定，治疗仍在进行。到目前为止，未发生严重不良反应。我们的病例证实了先前的报告，即PD-1检查点抑制剂对经过大量预处理的转移性CSCC患者具有临床疗效和耐受性。市售的PD-1检查点抑制剂可能对这些患者有用，应优先在临床试验中考虑对这些患者使用PD-1检查点抑制剂治疗。
